Health authorities, spearheaded by the Medicines and Healthcare products Regulatory Agency (MHRA), have issued a critical warning regarding GLP-1 medications, including popular drugs like Wegovy, Ozempic, and Mounjaro. The warning highlights an increased, albeit small, risk of developing severe acute pancreatitis, a painful and potentially fatal condition characterized by inflammation of the pancreas.

Acute pancreatitis manifests over a short period with typical symptoms such as extreme, persistent pain in the stomach and back, which may radiate and can be accompanied by fever and vomiting. The pancreas, a pear-shaped organ located behind the stomach, plays a vital role in producing digestive enzymes and insulin. While most patients experiencing pancreatitis begin to recover within a week, some can develop severe complications, including necrosis where pancreatic tissue begins to die. This can lead to further serious conditions such as infection, sepsis, organ failure, and ultimately, death.

The MHRA has updated the product information for these medications to explicitly include this small but severe risk. Users are strongly advised to seek immediate medical attention if they experience any of the aforementioned symptoms. This illness, though known, is an infrequent side effect, but its potential severity underscores the importance of prompt diagnosis and treatment.

A tragic example highlighting these risks is the case of Susan McGowan, a 58-year-old nurse from Lanarkshire, who died in September 2024 from multiple organ failure, septic shock, and pancreatitis. Her death occurred after she had taken two low-dose injections of tirzepatide, marketed as Mounjaro. Her death certificate listed acute pancreatitis as one of the immediate causes of death, with her use of Mounjaro (tirzepatide) recorded as a contributing factor. This marked the first death officially linked to the drug in the UK.

Following this incident, Dr. Alison Cave, the chief safety officer for the MHRA, expressed sympathy for Susan McGowan's family. However, she reaffirmed the agency's stance that, based on current evidence, the benefits of these drugs generally outweigh the potential risks when used for their licensed indications. Dr. Cave emphasized that patient safety is the MHRA's top priority, and the agency continuously monitors the safety and efficacy of all licensed medicines.

GLP-1 receptor agonists, the class of drugs to which Wegovy, Ozempic, and Mounjaro belong, function by mimicking the natural hormone GLP-1 to regulate blood sugar and insulin levels. Initially developed as a treatment for type 2 diabetes, a number of these medications, including semaglutide (Wegovy) and tirzepatide (Mounjaro), are now recommended on the NHS to aid in weight loss. In England, Wales, and Scotland, an estimated 1.6 million people have used these drugs within the last year.

Dr. Cave reiterated that for the vast majority of patients, GLP-1s are safe and effective, delivering significant health benefits. Nevertheless, she stressed the importance for both patients and healthcare professionals to be fully aware and alert to the associated symptoms of pancreatitis. Patients experiencing severe, persistent stomach pain that may radiate to the back, accompanied by nausea and vomiting, are advised to speak to a healthcare professional immediately and to report any such adverse reactions via the Yellow Card scheme.